NCT05602831 - Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

August 31, 2024

Conditions

Locally Advanced Cervical Cancer

Interventions

OTHER

detect HPV and genetic variants

Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.

OTHER

detect HPV and genetic variants

Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.

Trial Locations (1)

200023

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai